Physician profile
Neriy Izkhakov
NPI 1366974750
$4,059.80
in general payments reported to CMS, 2019-2025
28 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.45 · 2022: $278 · 2023: $837 · 2024: $783 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.60 |
| Education | $132.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.97 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $402.22 | 2023-2025 | Tymlos |
| Medtronic, INC. | $385.09 | 2022-2025 | Minimed 780g |
| Amgen INC. | $295.46 | 2023-2025 | Tepezza, Repatha, Evenity |
| Alexion Pharmaceuticals, INC. | $214.82 | 2023-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $214.32 | 2022-2025 | |
| Abbvie INC. | $204.05 | 2024-2025 | |
| Horizon Therapeutics Plc | $184.27 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $178.06 | 2024-2025 | Yorvipath |
| Mannkind Corporation | $171.21 | 2023-2025 | Afrezza |
| Kyowa Kirin, INC. | $156.67 | 2023 | |
| Lilly USA, LLC | $123.74 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $121.06 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $114.33 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $111.23 | 2022-2025 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $93.57 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Chiesi USA, INC. | $57.87 | 2025 | Mycapssa |
| Sanofi-Aventis U.S. LLC | $54.23 | 2025 | |
| Sequel Med Tech, LLC | $53.77 | 2025 | Twiist |
| Beta Bionics, INC. | $39.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascensia Diabetes Care US INC. | $39.13 | 2024-2025 | |
| Abbott Laboratories | $38.26 | 2021-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $35.15 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $33.64 | 2022 | |
| Corcept Therapeutics | $25.11 | 2025 | Korlym |
| Recordati_rare_diseases_inc. | $22.60 | 2025 | Isturisa |
| Acella Pharmaceuticals, LLC | $17.38 | 2025 | NP Thyroid 60 |
| Ibsa Pharma INC. | $15.08 | 2025 | Tirosint, Flector, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neriy Izkhakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.